Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother.
MorphoSys, partnered with the New Jersey drugmaker’s Janssen unit, said Tuesday that the drug giant had started up a phase 2/3 clinical trial program in Crohn’s disease, reaching for an indication that J&J immunology blockbuster Stelara bagged in 2016.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,